Close
CDMO Safety Testing 2026
Novotech

Clinerion and Medexprim join forces to combine clinical and imaging data for research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

BeOne Signs $2B Trispecific Antibody Deal with Huahui Health

BeOne Medicines has entered into a high-value agreement with...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.
- Advertisement -

Clinerion and Medexprim have concluded a three-year partnership dedicated to the merger of electronic health records and imaging data into a private clinical data cloud warehouse dedicated to research.

Clinerion is the worldwide leader in medical data informatics, radically improving efficiency in patient search and identification, increasing effectiveness in clinical research and accelerating the process of drug development to ensure an earlier availability of medicines.

Medexprim, the European expert in generating regulatory-grade datasets of aggregated images and clinical data, builds bridges between hospitals and biopharmaceutical companies to accelerate clinical research, and helps biopharmaceutical companies access specific datasets and design more successful, cost effective and faster clinical trials.

Clinerion and Medexprim will set up a joint offering which allows access to de-identified, enriched, longitudinal data points derived from complex medical data sets, which combine electronic health records and their corresponding clinical images, to improve research and help patients receive better care. This collaboration will accelerate and expand Clinerionโ€™s and Medexprimโ€™s networks of hospital partners and accelerate the implementation of a clinical data warehouse globally accessible via a proprietary cloud.

The value of imaging data is recognized for its high clinical utility and value in the end-to-end evidence management process, notably in oncology, which is the top therapeutic area for clinical trials. Bar?? Erdo?an, CEO of Clinerion, says: โ€œWe are delighted to have partnered with Medexprim as we see a tremendous value in associating our access to the millions of electronic health records of our patients with their associated clinical images. We are keen to continue providing context to the pharmaceutical industry on disease development, tumor stages and rare diseases, and deliver high resolution information resulting from these two data classes. Ultimately, Clinerion is continuing to fulfil its mission of enabling a more granular patient data access for pre-screening, site selection and trial design, as well as providing much richer disease information to the clinical value chain.โ€

Romain Cazavan, CEO of Medexprim, says: โ€œWe are more than happy to announce our partnership with Clinerion. Clinerion’s and Medexprimโ€™s complementary expertise will enable more European university hospitals to leverage their Real-World data and will accelerate the implementation of a clinical data warehouse in the service of clinical research and the well-being of patients. Medical imaging plays an instrumental role in clinical research: imaging is a non-invasive tool, it allows screening and stratification of patients, can reduce study budget and drug development time and accelerate regulatory approvals. Medexprim specializes in extracting complex datasets composed of clinical data, images, biology and genomics based on retrospective data. We aim to create multicentric and multiomics data lakes per disease, develop imaging biomarkers to diagnose and evaluate treatment response, introduce some biostatistics methodology to identify new patients to be included in clinical research studies but also to build synthetic control arms.”

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.

Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerionโ€™s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerionโ€™s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Latest stories

Related stories

BeOne Signs $2B Trispecific Antibody Deal with Huahui Health

BeOne Medicines has entered into a high-value agreement with...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum Computing Optimizing Pharma Supply Chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป